Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin May Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

DefiniGEN Raises £1.5M ($2.29M USD) in Follow-on Funding

publication date: Jun 24, 2016
 | 
author/source: DefiniGEN

Investment will be used to fund commercial launch of new pancreatic and lung stem cell products for drug discovery and regenerative medicine

definigenDefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The round was led by Cambridge Enterprise, the commercialization arm of the University of Cambridge, and 24 Haymarket, with key investors Dr Jonathan Milner (Chairman), Providence Investment Company, Parkwalk, and Cambridge Capital Group also participating. This funding follows the closing of £2.28 million ($3.83 million) Series A funding in 2014.

DefiniGEN is focused on serving the growing need in the pharmaceutical industry for more accurate predictions of efficacy and toxicity in drug candidates ahead of clinical trials. Its platform technology OptiDIFF is a revolutionary stem cell production platform for the generation of high-functionality cell types including, liver, pancreatic and lung cells. These cells can be used as predictive in vitro models to support the development of safer and more effective treatments for diseases. The new funding will help drive DefiniGEN to profitability and enable the Company to achieve the following:

  • Delivery of ground-breaking cryopreserved pancreatic beta cell products to the global diabetes drug development market
  • Development of lung and intestinal cell products to assist the development of treatments for major genetic diseases, such as cystic fibrosis
  • Expansion of business development in North America, Europe, and Asia Pacific with dedicated local marketing presence
  • Recruitment of high-quality production staff and invest in up-scaled production at the Company’s enlarged laboratory facilities
  • Strengthening of the Company’s intellectual property portfolio

Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN said: “In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease.”

Dr Jonathan Milner, Chairman of DefiniGEN and formerly CEO of Abcam Plc, said: “DefiniGEN is harnessing the power of stem cell technology to develop products that are transformational for drug discovery, enabling the accelerated development of therapies that can beneficially transform the lives of afflicted people.”


more about definigen


 

 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners